Goldman Sachs released a research report stating a "buy" rating for CSPC Pharma (01093), with a target price of 10.03 Hong Kong dollars. The company aims to complete 1-2 BD transactions by 2024, emphasizing continuous review of product lines, strengthening business expansion efforts, and the bank expects more transactions to occur in the future.
The bank pointed out that CSPC Pharma announced plans to authorize YS2302018 (a small molecule inhibitor of lipoprotein (a) (Lpa) in preclinical stage) and any products containing YS2302018 globally. The company's first collaboration with Astrazeneca is seen by the bank as an important step in the company's global expansion process.
